Calcium (500mg) + Calcitriol (0.25mcg) + Zinc (20mg) + Ibandronic Acid (150mg) (Medical Monograph)

Overview

A fixed-dose combination therapy for the management of postmenopausal osteoporosis and other bone disorders. It provides a comprehensive approach by combining a bisphosphonate (Ibandronic Acid) for bone resorption inhibition with essential bone-building minerals (Calcium, Zinc) and the active form of Vitamin D (Calcitriol) to enhance calcium absorption and bone mineralization. This combination addresses multiple facets of bone metabolism and is a cornerstone of osteoporosis management in the Indian context, where dietary deficiencies are common.

The combination exerts a multi-targeted effect on bone remodeling. Ibandronic Acid potently inhibits osteoclast-mediated bone resorption by disrupting the mevalonate pathway, leading to osteoclast apoptosis. Calcitriol (1,25-dihydroxyvitamin D3) enhances intestinal absorption of calcium and phosphate, promotes renal tubular reabsorption of calcium, and directly stimulates osteoblasts for bone formation. Calcium provides the essential mineral substrate for bone mineralization. Zinc acts as a cofactor for over 300 enzymes, including alkaline phosphatase and collagenase, crucial for bone matrix synthesis and mineralization.